1. Academic Validation
  2. Fragment-Based Discovery of Novel VE-PTP Inhibitors Using Orthogonal Biophysical Techniques

Fragment-Based Discovery of Novel VE-PTP Inhibitors Using Orthogonal Biophysical Techniques

  • Biochemistry. 2023 Jul 18;62(14):2161-2169. doi: 10.1021/acs.biochem.3c00079.
Wataru Asano 1 Kenji Yamanaka 1 Yasunori Ohara 1 Toru Uhara 1 Satoki Doi 2 Takuya Orita 2 Tomoko Iwanaga 2 Tsuyoshi Adachi 2 Shingo Fujioka 2 Tatsuo Akaki 2 Kazutaka Ikegashira 2 Yoshiji Hantani 1
Affiliations

Affiliations

  • 1 Biological/Pharmacological Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan.
  • 2 Chemical Research Laboratories, Central Pharmaceutical Research Institute, Japan Tobacco Inc., 1-1 Murasaki-cho, Takatsuki, Osaka 569-1125, Japan.
Abstract

Tyrosine phosphorylation is an essential post-translational modification that regulates various biological events and is implicated in many diseases including Cancer and atherosclerosis. Vascular endothelial protein tyrosine Phosphatase (VE-PTP), which plays an important role in vascular homeostasis and angiogenesis, is therefore an attractive drug target for these diseases. However, there are still no drugs targeting PTP including VE-PTP. In this paper, we report the discovery of a novel VE-PTP inhibitor, Cpd-2, by fragment-based screening combining various biophysical techniques. Cpd-2 is the first VE-PTP inhibitor with a weakly acidic structure and high selectivity, unlike known strongly acidic inhibitors. We believe that this compound represents a new possibility for the development of bioavailable VE-PTP inhibitors.

Figures
Products